Results 211 to 220 of about 216,867 (346)
Enhanced editing of <i>Bifidobacterium lactis</i> using the endogenous Type I-G CRISPR-Cas system. [PDF]
Raftopoulou O +3 more
europepmc +1 more source
Hypertrophic scar formation is driven by excessive mitochondrial fission in wound macrophages, which we discover is governed by a novel AURKB‐DRP1(Ser616) axis. The study develops a targeted therapy using cRGD‐decorated extracellular vesicles to deliver the natural compound Asiaticoside specifically to macrophages.
Luyu Li +8 more
wiley +1 more source
Characterization and engineering of a type IV-A3 CRISPR-Cas system for genome editing in Escherichia coli. [PDF]
Semsey S +11 more
europepmc +1 more source
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Association of the existence of CRISPR-Cas system and antimicrobial resistance in multi-drug resistant Klebsiella pneumoniae in Egypt. [PDF]
El Menofy NG +3 more
europepmc +1 more source
A Functionally Conserved Enhancer is Critical for PGC1A Expression and Thermogenesis in Brown Fat
An evolutionarily conserved enhancer controls PGC1A expression and thermogenic activation in brown adipose tissue. Integrative multi‐omics analyses identify two BAT‐specific enhancers, with PGC1A‐En1 functioning as the dominant regulatory element that maintains thermogenic capacity across species.
Duo Su +10 more
wiley +1 more source
Research progress of base editing and prime editing tools based on the CRISPR/Cas system. [PDF]
Gao H +4 more
europepmc +1 more source
This study developed a novel drug delivery platform that overcomes the blood‐brain barrier in glioblastoma. By fusing IGFBP7 with small extracellular vesicles, the platform specifically targets tumor vasculature. It effectively delivers temozolomide, suppressing tumor growth at low doses.
Lingling Liu +17 more
wiley +1 more source
Recent applications, future perspectives, and limitations of the CRISPR-Cas system. [PDF]
Park SJ, Lee GE, Cho SM, Choi EH.
europepmc +1 more source

